Clinical trial · Interventional
Evaluating the Utility of the Apoptosis Imaging Biomarker 18F]ML10 in Patients With Non-Hodgkin's Lymphoma(NHL)
An Open-label Study to Evaluate the Utility of the Apoptosis Imaging Biomarker 18F]ML10 to Assess the Response to Chemotherapy in Patients With Non-Hodgkin's Lymphoma(NHL).
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study terminated as ongoing analysis suggested objectives not practical to achieve with study as implemented
Summary
Brief summary (as posted)
This study aims to evaluate the potential of 2-(5- Fluoro pentyl)-2-methyl malonic acid (\[18F\]ML10), as an apoptosis imaging biomarker and its potential to predict response in patients with Non Hodgkin's Lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ML10 | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- NO_INTERVENTION
- label
- no treatment
- description
- no treatment
- interventionNames
- Radiation: ML10
Primary outcomes (1)
- measure
- changes in [18F]ML10 uptake in tumours
- timeFrame
- between baseline at day 0 and between 14-20 days after
- description
- Extent of changes in \[18F\]ML10 uptake in tumours following chemotherapy using visual and semi-quantitative parameters.
Secondary outcomes (2)
- measure
- alterations in [18F]ML10 uptake with tumour volume and tumour metabolic changes
- timeFrame
- between baseline at day 0 and between 14-20 days after
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Capable of giving written informed consent, and willing and able to comply with the requirements and restrictions listed in the consent form. 2. Male or female patients \>18 years of age at screening with histological or cytological diagnosis of Non-Hodgkin's Lymphoma and due to receive intravenous chemotherapy for the first time 3. A female subject is eligible to participate if she has non-childbearing potential 4. Male subject must agree to use one of the contraception methods listed 5. Able to lie comfortably on back for up to 70 minutes at a time. 6. WHO performance status 0, 1 or 2 - Exclusion Criteria: 1. Patients with known history of Hepatitis B, C, non-A, non-B and HIV 2. Any clinically significant medical conditions that in the opinion of the investigator would compromise the compliance with study procedures. 3. Pregnant or breast feeding females. 4. Any other prior anticancer therapy 5. Any new investigational agent, including an investigational anti-cancer agent 6. History of sensitivity to heparin or heparin-induced thrombocytopenia. 7. Males and females not able to comply with contraceptive guidelines during the study. \-
References
Publications (0)
Data not yet available